Literature DB >> 11788451

FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells.

Noriyoshi Kobayashi1, Yusuke Suzuki, Toshinao Tsuge, Ko Okumura, Chisei Ra, Yasuhiko Tomino.   

Abstract

In the kidney, proteins filtered through glomeruli are reabsorbed by endocytosis along the proximal tubules to avoid renal loss of large amounts of proteins. Recently, neonatal Fc receptor (FcRn), which is involved in the transport of IgG across several epithelial and endothelial cells, was reported to be expressed in renal proximal tubular epithelial cells (RPTECs). However, there has been no direct evidence for receptor-mediated endocytosis of IgG in human RPTECs. To explore physiological roles of FcRn in the proximal tubules, we used the human RPTECs to examine IgG transport. FcRn was expressed in RPTECs and physically associated with beta(2)-microglobulin, preserving the capacity of specific pH-dependent IgG binding. Human IgG was bound to the cell surface of RPTECs in a pH-dependent manner. The human IgG transport assay revealed that receptor-mediated transepithelial transport of intact IgG in RPTECs is bidirectional and that it requires the formation of acidified intracellular compartments. With the use of double immunofluorescence, the internalized human IgG was marked in cytoplasm of RPTECs and colocalized with FcRn. These data define the mechanisms of FcRn-associated IgG transport in RPTEC monolayers. It was suggested that the intact pathway for human IgG transepithelial transport may avoid lysosomal degradation of IgG.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11788451     DOI: 10.1152/ajprenal.0164.2001

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  46 in total

1.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-06       Impact factor: 2.745

2.  Bidirectional transepithelial IgG transport by a strongly polarized basolateral membrane Fcgamma-receptor.

Authors:  Steven M Claypool; Bonny L Dickinson; Jessica S Wagner; Finn-Eirik Johansen; Nanda Venu; Jason A Borawski; Wayne I Lencer; Richard S Blumberg
Journal:  Mol Biol Cell       Date:  2004-02-06       Impact factor: 4.138

3.  Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level.

Authors:  Raimund J Ober; Cruz Martinez; Xuming Lai; Jinchun Zhou; E Sally Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-16       Impact factor: 11.205

Review 4.  Population pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Nathanael L Dirks; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Ron J Keizer; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

6.  From sorting endosomes to exocytosis: association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling.

Authors:  E Sally Ward; Cruz Martinez; Carlos Vaccaro; Jinchun Zhou; Qing Tang; Raimund J Ober
Journal:  Mol Biol Cell       Date:  2005-02-02       Impact factor: 4.138

Review 7.  How the controller is controlled - neonatal Fc receptor expression and immunoglobulin G homeostasis.

Authors:  Shuo-Wang Qiao; Wayne I Lencer; Richard S Blumberg
Journal:  Immunology       Date:  2006-11-28       Impact factor: 7.397

8.  The fusion protein of respiratory syncytial virus triggers p53-dependent apoptosis.

Authors:  Julia Eckardt-Michel; Markus Lorek; Diane Baxmann; Thomas Grunwald; Günther M Keil; Gert Zimmer
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

Review 9.  Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn.

Authors:  E Sally Ward; Raimund J Ober
Journal:  Adv Immunol       Date:  2009       Impact factor: 3.543

Review 10.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.